Allogene Therapeutics, Inc.

Análisis de la acción Allogene Therapeutics, Inc. (ALLO)

$1.330

+0.031 (+2.31%)Al cierre

Loading chart…
Máximo
1.350
Apertura
1.300
Precio medio ponderado por volumen
1.33
Volumen
4.51M
Capitalización
509.43M
Mínimo
1.297
Importe
5.98M
EV/EBITDA, TTM
-4.38

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.

allogene.com

Análisis de IA of Allogene Therapeutics, Inc. (ALLO)

Vender

Allogene Therapeutics is not a good buy right now. The current price is $1.31, and the company has reported consistent losses, including a net income loss of $42,677,000 in Q2 2026. Additionally, the RSI is at 27.381, indicating that the stock is oversold, but this does not guarantee a price rebound. The main risk is the ongoing financial strain reflected in a negative forward P/E ratio of 0, suggesting that the company is not expected to generate profits in the near future.

Recomendaciones de analistas (4)

+539.10% de potencial alcista
Comprar
3 Comprar
1 Mantener
0 Vender
Actual: 1.33
Mínimo
5.00
Promedio
8.50
Máximo
14.00

JPMorgan

2026-04-16

Precio objetivo

—

Neutral

H.C. Wainwright

2026-04-16

Precio objetivo

$11

Comprar

Jefferies

2026-04-15

Precio objetivo

$10

Comprar

Baird

2026-04-14

Precio objetivo

$9

Superar al mercado

Bernstein

2026-04-14

Precio objetivo

—

Market Perform

Métricas de valoración

El PER previsto actual de Allogene Therapeutics, Inc. (ALLO) es 0.00, frente a su media de 5 años de -2.71.

PER previsto

Sobrevalorado
Media 5A P/E
-2.71
P/E actual
0.00
Sobrevalorada
-1.23
Infravalorada
-4.19

EV/EBITDA previsto

Infravalorado
Media 5A EV/EBITDA
-1.78
EV/EBITDA actual
-4.38
Sobrevalorada
-0.15
Infravalorada
-3.41

Precio/ventas previsto

Valor razonable
Media 5A P/S
24411.42
P/S actual
37.45
Sobrevalorada
91939.38
Infravalorada
-43116.54

Ballenas con ALLO en cartera

T

TPG Capital, L.P.

+ Con en carteraALLO

-7.21%

Rentabilidad a 3 meses

F

Frazier Life Sciences Management, LP

+ Con en carteraALLO

-17.65%

Rentabilidad a 3 meses

Cronología de eventos

2026-09-02 (ET)

09:00:00

Allogene Therapeutics CFO Geoffrey Parker to Retire on November 6

2026-08-12 (ET)

16:30:00

Allogene Reports Q2 Revenue of $4.64M, Exceeding Expectations

16:30:00

Allogene Therapeutics Files $500M Mixed Securities Shelf

2026-07-29 (ET)

09:00:00

Allogene Therapeutics Receives FDA RMAT and Fast Track Designations

2026-07-15 (ET)

09:30:00

Allogene Publishes Complete Phase 1 Data for ALLO-316

Noticias

Preguntas frecuentes sobre ALLO, respondidas por Alphio AI

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Allogene Therapeutics is not a good buy right now. The current price is $1.31, and the company has reported consistent losses, including a net income loss of $42,677,000 in Q2 2026. Additionally, the RSI is at 27.381, indicating that the stock is oversold, but this does not guarantee a price rebound. The main risk is the ongoing financial strain reflected in a negative forward P/E ratio of 0, suggesting that the company is not expected to generate profits in the near future.

4 analysts cover ALLO: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 8.50.

Comunidad

Más ↗
gigarollup8/10/2026

ALLO/USDT quickly shifted from excitement to exhaustion. $ALLO once surged to 0.35839, then fell for several days in a row. It is now at 0.25601, down 36.60% over 90 days. But it is still up 137.37% over 180 days. The bigger trend is green, the short-term trend is red. That gap is exactly what makes traders lose discipline. Are you trading ALLO’s trend, or its pullback?

Mostrar más
squeezeecho23/9/2026

$LIT $ALLO $RAY Success in crypto, I've learned, isn't about chasing every opportunity — it's about patience, discipline, and having a clear strategy. After losing more than $9,500 trading on my own, I genuinely questioned whether I should continue. Following CY WATSON's market insights changed my approach completely. I became more disciplined, paid closer attention to market structure and timing, and learned to avoid emotional decisions. Through his copy-trading approach, I've made significant profits today — I'm grossing a profit of $23,651 from CY WATSON by just copying his trades. Seeing this progress after the losses I experienced has been incredibly rewarding. Based on my own experience, I have a lot of respect for CY WATSON's approach and would confidently recommend people interested in learning about his methods to take time and reach out to him. His username is in the comments below for anyone who wants to take a look.

Mostrar más
chrome_nonce23/9/2026

$SENT $ALLO $CPOOL 🌎 MACRO IS ABOUT TO GET INTERESTING… Tonight’s market isn’t only about Bitcoin or gold. U.S. flash manufacturing and services PMI data are due, while Fed Vice Chair Michael Barr is also scheduled to speak. At the same time, oil remains around the $90 area and traders are watching developments around the Middle East and U.S.–China relations. 📊⚡ That combination can create some serious intraday volatility across BTC, ETH, gold and U.S. equities. So instead of asking, “Which coin is going 10x?” I’m asking: 👉 Where is liquidity sitting? 👉 Where are the major resistance zones? 👉 What happens if the data surprises? The next move may come from macro before crypto even gets the chance to react. 👀 #BTC #ETH #Gold #Macro #CryptoTrading

Mostrar más

Please, stop pumping, just give me a chance! I woke up and saw $AKE surging again, already near 0.06. Why is it so easy for it to bounce back after a drop? Everyone says the unlock will bring selling, but when everyone expects the same thing, the market makers won't let it play out that way. Because if it were really that easy, then $ALLO and $LAB would have done the same before — they kept pumping right before the unlock, and when the unlock day came, there was no sell-off either, just like $LAB ranging around 15 during that period.

Mostrar más
PerpBlock16/9/2026

Just switched the software to the background, and it dropped right away — playing hide-and-seek with me? Opened the chart this morning, $ALLO was clearly under pressure at the highs, with weak support, and the overhead resistance was suffocating. I called the long-high short idea at the time, and the rhythm was on point. If the trend isn't broken, hold; if it breaks, run. Don't fall in love with a stock. From 0.24914 to 0.20142, the short wasn't held in vain, +469.19%, feels great. It was really slow before, but once it played out, it was sweet. Closed 80% first, keeping the remaining 20% protected at cost. Let profits run if it keeps dropping, and don't let a bounce turn gains into discomfort. Take profits when it's time. Don't get inflated by profits, don't despair over drawdowns. There will be more opportunities later — don't chase, wait for a more comfortable position next round. I'll flag it as soon as I see it. $ETH $XRP

Mostrar más
Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar